The dual-function phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is the second most frequently mutated gene in human cancers. PTEN counteracts the functions of many growth factors, the most prevalent of which is insulin-like growth factor II (IGF-II). PTEN expression is stimulated by IGF-II forming a feedback loop. Investigating IGF-binding protein (IGFBP) modulation of IGF-II actions on MCF-7 breast cancer cells, we found that IGFBP-2 also regulates PTEN. The MCF-7 cells were not responsive to high doses of IGF-II due to induction of PTEN, which was not observed with an IGF-II-analog that does not bind to IGFBPs or in the presence of an inhibitor that prevents IGFs associating with IGFBPs. These cells predominantly produce IGFBP-2: blocking IGFBP-2 with a specific antibody, or preventing IGFBP-2 binding to integrins, restored the induction of PTEN and the cells were non-responsive to high doses of the IGF-II-analog. Our findings indicate that breast cancer cells do not respond to high doses of IGF-II due to induction of PTEN, but IGFBP-2, when free from IGF-II can suppress PTEN. Levels of IGFBP-2 are elevated frequently in human tumors: its ability to regulate PTEN could have important implications in relation to therapeutic strategies targeting growth factor pathways.
The dual-function phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is the second most frequently mutated gene in human cancers. PTEN counteracts the functions of many growth factors, the most prevalent of which is insulin-like growth factor II (IGF-II). PTEN expression is stimulated by IGF-II forming a feedback loop. Investigating IGF-binding protein (IGFBP) modulation of IGF-II actions on MCF-7 breast cancer cells, we found that IGFBP-2 also regulates PTEN. The MCF-7 cells were not responsive to high doses of IGF-II due to induction of PTEN, which was not observed with an IGF-II-analog that does not bind to IGFBPs or in the presence of an inhibitor that prevents IGFs associating with IGFBPs. These cells predominantly produce IGFBP-2: blocking IGFBP-2 with a specific antibody, or preventing IGFBP-2 binding to integrins, restored the induction of PTEN and the cells were non-responsive to high doses of the IGF-II-analog. Our findings indicate that breast cancer cells do not respond to high doses of IGF-II due to induction of PTEN, but IGFBP-2, when free from IGF-II can suppress PTEN. Levels of IGFBP-2 are elevated frequently in human tumors: its ability to regulate PTEN could have important implications in relation to therapeutic strategies targeting growth factor pathways. Oncogene (2007) 26, 5966-5972; doi:10.1038/sj.onc.1210397; published online 19 March 2007 Keywords: IGF-II; IGFBP-2; PTEN In addition to the oncogenic potential of several tyrosine kinases, there are phosphatases with tumor suppressor activity. One of the first phosphatases that was heavily implicated in human cancers is the phosphatase and tensin homolog deleted on chromosome 10 (PTEN). PTEN is one of the most frequently mutated tumor suppressor genes (Stambolic et al., 1998; Di Cristofano and Pandolfi, 2000) and can lead to tumor initiation, as evidenced by the inherited cancer syndromes resulting from germline mutations, and also promote tumor progression and metastases with many somatic mutations or deletions being associated with higher grades of cancers. PTEN is a dual function protein and lipid phosphatase. It dephosphorylates the phospholipids generated by the oncogenic phosphatidylinositol 3-kinase (Pl3-kinase) and its protein phosphatase activity can suppress mitogen-activated protein kinase (MAPK) signaling (Gu et al., 1998; Weng et al., 2002) . PTEN can therefore counter the survival and proliferative actions of many growth factors. Considerable is known regarding the growth factors that activate these signaling pathways, although in contrast, much less is known regarding the mechanisms that deactivate them. PTEN has an important role in human cancers and there have been many studies documenting genetic defects, but there have so far been few reports identifying factors that control PTEN levels. PTEN transcription is controlled by p53 (Stambolic et al., 2001) and Egr-I (Virolle et al., 2001) . One of the few external controls that has been identified is insulin-like growth factor II (IGF-II) (Moorehead et al., 2003) ; probably the most prevalent growth factor present in human tissues that activates the signaling pathways which PTEN itself then deactivates. PTEN can also downregulate IGF-II expression (Kang-Park and Lee, 2003; Hwang et al., 2005) , suggesting a tightly controlled feedback loop in which IGF-II can enhance PTEN expression and PTEN can suppress IGF-II expression. While investigating the responses of human breast cancer cells, MCF-7, to IGF-II we have discovered a further mechanism of feedback and an additional novel regulator of PTEN.
Initial studies with MCF-7 cells revealed that increasing doses of IGF-II stimulated cell metabolic activity, proliferation and DNA synthesis up to a dose of 75-100 ng/ml, but at higher doses the responses were reduced (Figures 1a and b) . At a dose of 500 ng/ml of IGF-II, the stimulation of DNA synthesis was less than that observed at 10 ng/ml. We observed a different response with an IGF-II analog, Des(1-6)IGFII (Des), that activates the IGF-I receptor, but which has very little affinity for IGFbinding proteins (IGFBPs). At a dose of 500 ng/ml, the metabolic, proliferative and DNA synthesis response to Des was significantly greater than IGF-II. We have also repeated these experiments with T47D human breast cancer cells with very similar results; the cells were desensitized to 500 ng/ml IGF-II, but not to the same dose of Des (Figure 1c ). When the same experiment was, however, repeated with IGF-I and an equivalent IGF-I analog (Long R 3 -IGF-I: LR3) with much reduced affinity for IGFBPs, the response to both these forms of IGF-I was identical with reduced sensitivity at higher doses (Figure 1d ). This suggested that either a cell-derived IGFBP was preventing the desensitization to IGF-II, but not IGF-I, or a more complex interaction was involved.
To further verify that an interaction with an IGFBP was responsible for the discordant response to high doses of the two forms of IGF-II, we used NBI-31772, a non-peptide ligand that displaces IGFs from all six IGFBP . When MCF-7 cells were exposed to increasing concentrations of wild-type IGF-II in the presence of NBI-31772, the loss of sensitivity to higher doses was no longer observed and the response to wild-type IGF-II was now identical to the response to Des (Figure 1e ). This appeared to confirm that the For caption see next page discordant response was due to an IGFBP. We then examined MCF-7 cell conditioned medium to establish the IGFBPs that they produced. On a Western ligand blot ( Figure 1f ) one prominent band appeared to correspond to one major IGFBP with a molecular weight of around 32 kDa. This corresponded to the size of IGFBP-2, the identity of which was confirmed on an immunoblot using a specific IGFBP-2 antibody, consistent with findings from others (Dubois et al., 1995) . Levels of IGFBP-2 in conditioned medium were monitored at 24 and 48 h and did not vary between cells treated with IGF-II or Des (data not shown).
We utilized a blocking antibody to negate IGFBP-2 actions, and in its presence the MCF-7 response to wildtype IGF-II was markedly inhibited (Figure 2a ). We believe that this was due to the antibody sequestering the IGFBP-2:IGF-II complex and therefore restricting IGF-II activity. When cells were stimulated with Des, which could not be sequestered with the IGFBP-2, the presence of the IGFBP-2 antibody then reverted the cell response, so that it now resembled wild-type IGF-II ( Figure 2b , compare arrowed columns), with a complete loss of sensitivity of the cells to the high concentration of Des. This suggested that IGFBP-2 was responsible for the loss of desensitization to IGF-II, but this was only apparent when IGFBP-2 could not bind to the IGF-II. This is analogous to several actions of other IGFBPs that are prevented by IGF binding. For example, we have previously shown that IGFs prevent the binding of IGFBP-3 to breast cancer cells and negate its actions (Maile et al., 1999) .
We and others have previously reported that IGFBP-2 acts independently of IGF on human breast cancer cells by an interaction with a5b1 integrin receptors via the arginine-glycine-aspartate (RGD) sequence in its Cterminal domain (McCaig et al., 2002; Schutt et al., 2004) . We prevented IGFBP-2 binding to integrin receptors using a short RGD-containing disintegrin peptide (Figure 2c ). Although the response to wild-type IGF-II was unaffected by this peptide, the response to 500 ng/ml Des was markedly reduced, reverting to that of wild-type IGF-II. These preliminary results are consistent with IGFBP-2 acting via an integrin receptor to prevent the desensitization to high-dose IGF-II stimulation.
To understand the discordant responses to high concentrations of Des and IGF-II, we initially examined the two main IGF-activated intracellular signaling pathways, namely the Pl3-kinase and MAPK cascades. No differences in levels of activated phospho(p)-Akt and p-MAPK P42/P44 were observed between cells treated with Des or IGF-II (data not shown), indicating that the loss of sensitivity to IGF-II at high concentrations was not due to less receptor activation or immediate downstream signaling activity. This suggested that IGFBP-2 was not limiting IGF-II from binding and activating cell receptors. Following the recent report demonstrating IGF-II feedback control of PTEN in mouse mammary glands (Moorehead et al., 2003) , we then examined the response of PTEN in our system. We also confirmed that in MCF-7 cells, IGF-II induced a marked increase in PTEN levels on Western blots that was apparent at 1 and 4 h (Figure 3a) , which was not however observed when the cells were treated with Des. This suggested that Des was activating the receptor and downstream signaling in the same way as IGF-II, but there was no desensitization due to prevention of the feedback increase in PTEN, and that this was due to IGFBP-2, to which the Des could not bind. When we repeated this in the presence of the IGFBP-2 blocking antibody, Des induced an increase in PTEN similar to that seen with wild-type IGF-II (compare arrowed lanes in Figure 3a) , indicating that IGFBP-2 was preventing the Desinduced increase in PTEN. The IGFBP-2 antibody also slightly increased the PTEN response to IGF-II at 1 h indicating that IGFBP-2 was partially limiting this response. Similar IGF-II induction of PTEN levels were observed in T47D cells and again this induction was less marked with Des (data not shown).
The loss of sensitivity to high concentrations of IGF-II was associated with an increase in PTEN, but no /well) were plated in six-well dishes in GM for 24 h. After a further 24 h in serum-free medium (SFM), the cells were dosed with increasing concentrations (0-500 ng/ml) of IGF-II or Des (GroPep, Adelaide, Australia). Cells were then counted with a hemocytometer. (b) Trititated thymidine incorporation (TTI) as described in Clark et al. (2005) as a measure of DNA synthesis in MCF-7 cells treated for 24 h with IGF-II or Des (0-500 ng/ml) or (c) T47D cells treated similarly. At a dose of 500 ng/ml, the cell responses to IGF-II and Des shown in (a-c) were significantly different (Po0.05, analysis of variance). (d) MTT (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide; Thiazolyl blue) assay for metabolic activity of MCF-7 cells as described previously (Clark et al., 2005) . Cells were seeded in 96-well plates at 7.5x10 3 cells per well for 24 h and the growth media then replaced with SFM for a further 24 h. Wells were dosed with increasing concentrations (0-500 ng/ml) of IGF-I or LR3 IGF-I (GroPep) for 24 h in triplicate. MTT reagent (7.5 mg/ml) was then added to the cultures and incubated for 30 min at 371C. The reaction was stopped by the addition of acidified triton buffer. The samples were measured on a Bio Rad, Hemel Hempstead, Hertfordshire, UK, 450 plate reader (test wavelength 595 nm, reference wavelength of 650 nm, Herts, UK). (e) NBI-31772 alters growth response to IGF-II. Cells were pre-dosed for 1 h with 0.1 mM NBI-31772 then re-dosed with either SFM or IGF-II (50-500 ng/ml). TTI was performed as described above. ) were grown to 60% confluence in T25 cm 2 flasks and then incubated in SFM for a further 24 h. The conditioned media was concentrated on Centricon filters (molecular weight cut off 5000 Da; Millipore, Billerica, MA, USA) and loaded (relative to protein concentration of lysates (50 mg)) in duplicate, separated on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis non-reducing gels and transferred to Hybond N þ nylon membranes (Amersham, Little Chalfont, Buckinghamshire, UK). Ligand blots were performed as described previously and exposed to autoradiograph film for 24 h (Coulson et al., 1991) . Membranes were also probed with anti-IGFBP-2 rabbit polyclonal (Santa Cruz Biotechnology, Bucks, UK) to confirm the identity of IGFBP-2.
For Figure see previous page change in activation of Akt or MAPK, suggesting no loss of the mitogenic signal, but a block in cell-cycle progression. It has been reported that PTEN regulates the expression of the cyclin-dependent kinase inhibitor, p21 WAF1 (Wu et al., 2000) and we therefore examined p21 levels by Western blotting (Figure 3b) . At 4 and 24 h, p21 levels increased following exposure to 500 ng/ml Des, but not to wild-type IGF-II. A sustained growth response to Des, at a dose at which sensitivity to wildtype IGF-II was lost, was therefore associated with a decrease in PTEN, but an increase in p21. Previously, it has been reported that in MCF-7 cells, p21 counterintuitively contributes to the proliferative response to IGF-I (Dupont et al., 2003) consistent with its known dual role in the cell-cycle (Sherr and Roberts, 1999) . We have previously confirmed that IGF-I stimulates p21 levels and growth of MCF-7 cells and p21 only switches to inhibit cell-cycle progression when the cells are stressed (Clark et al., 2005) . Our current findings are consistent with IGFBP-2 (independently from IGF binding) stimulating an increase in p21 via a reduction in PTEN, which then potentiates the mitogenic response to IGF-II. It has been reported that PTEN increases the expression of p21 and also its upstream regulator p53 (Freeman et al., 2003) . It has, however, been reported recently that acute loss of PTEN results in increased p53, increased p21 and cell senescence (Chen et al., 2005) . To establish whether a similar mechanism was operating in our models, we have employed a bisperoxovanadium phosphatase inhibitor, bpV(HOpic), at a Figure 2 Desensitization to high-dose Des is restored by anti-IGFBP-2 antibody or RGD peptide. Cells were plated and subjected to SFM conditions as in Figure 1 for measurement of TTI (a and b) were pre-dosed for 1 h with a mouse monoclonal anti-IGFBP-2 antibody (200 ng/ml) (Sandos Pharmaceuticals, Bazel, Switzerland), a control mouse IgG Ab (200 ng/ml) (Sigma, Dorset, UK) or SFM. Cells were then re-dosed with (a) IGF-II or (b) Des (50-500 ng/ml), þ /ÀIGFBP-2 Ab or þ /À control mouse IgG Ab for 24 h. (c) Cells were pre-dosed for 1 h with RGD (200 ng/ml) (Sigma) or SFM, then re-dosed with SFM and 50-500 ng/ml of IGF-II or Des.
concentration of 0.1 mm at which it is relatively specific for inhibiting PTEN, but not other phosphatases (Schmid et al., 2004) . In the presence of this inhibitor, the desensitization to IGF-II was prevented with the DNA synthesis similar to that induced by Des (Figure 3c ) and this was accompanied by a much greater IGF-II-induced increase in p21 compared to that seen without PTEN inhibited (Figure 3d and e) . This suggests that the IGF-II desensitization and absent p21 increase were mediated via PTEN activity. In the MCF-7 breast Figure 3 Differential response of PTEN and p21 to high-dose IGF-II and Des. Cells were set up as described in Figure 1f and (a) predosed for 1 h with IGFBP-2 Ab before the addition of SFM, or 500 ng/ml of IGF-II/Des, lysed at the time points indicated and lysates subjected to Western blotting for PTEN (26H9 Cell Signalling Technology, Beverly, MA, USA), or Glyceraldehyde-3-Phosphate dehydrogenase (anti-GAPDH; Chemicon Europe Ltd, UK) monoclonal antibodies according to manufacturers protocols. (b) Lysates were subjected to Western blotting for p21 (Cell Signaling, Herts, UK) and GAPDH and visualized by enhanced chemiluminescence according to manufacturer's instructions (Amersham). (c) Cells were plated and subjected to TTI measurements as in Figure 1b . Cells were pre-dosed for 5 min with 0.1 mM bpV(HOpic) (Calbiochem, Nottingham, UK) in SFM and subsequently co-dosed with bpV(HOpic) þ /À IGF-II or Des (500 ng/ml) for 24 h. (d) Cells were pre-dosed for 5 min with bpV(HOpic) followed by 4 h co-dosing þ /À IGF-II (500 ng/ml). Lysates were subjected to Western blotting for p21 and GAPDH (duplicates shown). One representative of three experiments shown. (e) Densitometry measurements of p21 levels as in (d). In the presence of bpV(HOpic), the response to IGF-II was significantly enhanced (Po0.04).
cancer cells, IGFBP-2 appears to block the IGF-IIinduced feedback increase in PTEN, which is then associated with an increase in p21, which in the context of MCF-7 cells mediates a mitogenic response to IGF-II (Figure 4) . In addition to suppression of Pl3-kinase and MAPK signaling it is now clear that PTEN can act in a variety of ways, some of which being completely independent of its protein or lipid phosphatase activity (Freeman et al., 2003; Stokoe and Costello, 2005) .
It has recently been reported that PTEN suppresses the expression of IGFBP-2 in glioma cells (Levitt et al., 2005) , which together with our new data suggest a further potential feedback loop with PTEN suppressing IGFBP-2 and IGFBP-2 induction of PTEN via an interaction with integrin receptors. An integrinmediated regulation of PTEN has been demonstrated previously in lung fibroblasts (White et al., 2003) .
PTEN plays an important role in many human tumors including the breast. In mouse models, deficiency of PTEN increases the susceptibility to mammary neoplasias (Li et al., 2001 ) and overexpression of PTEN in the mammary gland suppresses proliferation and enhances apoptosis (Dupont et al., 2002) . Approximately 50% of women with breast cancer have a mutation or a loss of at least one copy of the PTEN gene (Di Cristofano and Pandolfi, 2000) . The effect of PTEN appears to be dose responsive, a complete loss of PTEN is more frequent in metastatic cancer than in primary tumors (Di Cristofano and Pandolfi, 2000) , and in a mouse model of prostate cancer, the incidence and progression of cancers were found to be dramatically dependent upon the level of PTEN expression (Trotman et al., 2003) . PTEN status also greatly affects the response of breast tumors to chemotherapy, tamoxifen and herceptin and the development of resistance to these therapies (Clark et al., 2002; Nagata et al., 2004) . IGFBP-2 levels and expression are increased in a number of human cancers (Hoeflich et al., 2001) , and an association between tumor IGFBP-2 levels and breast cancer progression has been reported recently (Busund et al., 2005) . An increase in IGFBP-2 could block the feedback response of PTEN that protects from overstimulation by IGF-II, which could then contribute to tumor progression and the development of resistance to therapeutic interventions. The association of IGF-II with IGFBP-2 controls the availability of both peptides for interaction with the cell; their independent actions within the cell may then also induce counter-balancing responses.
